Market Scenario
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor and immune modulator, which is also known as colony stimulating factor 2. GM-CSF is produced by macrophages, T cells, endothelial cells, and fibroblasts. It promotes neutrophil maturation and proliferation. Neutrophils are the type of white blood cells important part of the innate immune system.
It is used as a supporting agent in cancer treatment increases the immunity in a cancer patient, use after bone marrow transplantation to stimulate white blood cell proliferation, also use in dendritic cell vaccines. The key factor responsible for influencing this market is the increasing prevalence of cancer, fungal infection, and unsuccessful skin grafting resolution.
According to the World Health Organization (WHO), in 2015, cancer was the second leading cause of death which can support the GM-CSF market growth. However, factors such as the high cost of chemotherapy treatments, and side effects associated with the drug are expected to restrict the market growth during the forecast period.
Key players
Some of the key players in the global granulocyte-macrophage-colony-stimulating factor market are Xconomy, Inc., Partner Therapeutics (PTx), and Sanofi-Aventis U.S. LLC, Novartis AG, Thermo Fisher Scientific, Merck KGaA and others.
Segmentation
The global granulocyte- macrophage colony-stimulating factor market is segmented on the basis of Route of administration, application, and end-user. The Granulocyte-macrophage colony-stimulating factor market, by route of administration, is sub-segmented into subcutaneous bolus and intravenous infusion. Granulocyte-macrophage colony-stimulating factor market on the bases of application it is segmented into fungal infections, skin-graft, cut-burn wounds, acute myelogenous leukemia and other. On the basis of end-user, the market is segmented into hospitals and clinics, surgical centers, diagnostic centers, research centers, and others.
More Details at https://www.marketresearchfuture.com/reports/granulocyte-macrophage-colony-stimulating-factor-market-6412
Regional Analysis
The Americas is the largest in the market owing to the increasing prevalence of cancer and growing healthcare expenditure. The American Cancer Society has estimated about 81,190 number of new cases of bladder cancer for 2018 in the United States in which about 18,810 will be women and 62,380 men. Such a high incidence of bladder cancer drives the market growth in this region.
Europe (UK, Belgium, France, and Netherlands) is the second largest granulocyte- macrophage colony-stimulating factor market during the forecast period. The increasing occurrence of head and neck cancer drives the market in this region. According, to the National Center for Biotechnology Information (2014) report recombinant human granulocyte-macrophage-colony-stimulating factor plays important role in wound healing. Also, it is beneficial for chronic leg ulcers, deep partial-thickness burn wounds, and leprosy ulcers. According to Cancer Research UK in 2015, there were12, 061 new cases of head and neck cancer. Thus, the growing cases of cancer facilitate the market growth.
Asia-Pacific was projected to be the fastest growing region for the global granulocyte- macrophage colony-stimulating factor market in 2017. The market is expected to witness growth owing to the rising prevalence of fungal infection and smoking in this region. According to the World Health Organization in 2015, 47.6% of people smoked tobacco in Japan and China, respectively which can increase the cancer patient in this region. This is expected to provide favorable backgrounds for the market to grow in this region.
The Middle East and Africa accounts for the least share due to lack of availability of well-trained healthcare facility and low per capita income. However, the rising fungal infection and other wound-related problems are expected to influence the market in a positive way.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor and immune modulator, which is also known as colony stimulating factor 2. GM-CSF is produced by macrophages, T cells, endothelial cells, and fibroblasts. It promotes neutrophil maturation and proliferation. Neutrophils are the type of white blood cells important part of the innate immune system.
It is used as a supporting agent in cancer treatment increases the immunity in a cancer patient, use after bone marrow transplantation to stimulate white blood cell proliferation, also use in dendritic cell vaccines. The key factor responsible for influencing this market is the increasing prevalence of cancer, fungal infection, and unsuccessful skin grafting resolution.
According to the World Health Organization (WHO), in 2015, cancer was the second leading cause of death which can support the GM-CSF market growth. However, factors such as the high cost of chemotherapy treatments, and side effects associated with the drug are expected to restrict the market growth during the forecast period.
Key players
Some of the key players in the global granulocyte-macrophage-colony-stimulating factor market are Xconomy, Inc., Partner Therapeutics (PTx), and Sanofi-Aventis U.S. LLC, Novartis AG, Thermo Fisher Scientific, Merck KGaA and others.
Segmentation
The global granulocyte- macrophage colony-stimulating factor market is segmented on the basis of Route of administration, application, and end-user. The Granulocyte-macrophage colony-stimulating factor market, by route of administration, is sub-segmented into subcutaneous bolus and intravenous infusion. Granulocyte-macrophage colony-stimulating factor market on the bases of application it is segmented into fungal infections, skin-graft, cut-burn wounds, acute myelogenous leukemia and other. On the basis of end-user, the market is segmented into hospitals and clinics, surgical centers, diagnostic centers, research centers, and others.
More Details at https://www.marketresearchfuture.com/reports/granulocyte-macrophage-colony-stimulating-factor-market-6412
Regional Analysis
The Americas is the largest in the market owing to the increasing prevalence of cancer and growing healthcare expenditure. The American Cancer Society has estimated about 81,190 number of new cases of bladder cancer for 2018 in the United States in which about 18,810 will be women and 62,380 men. Such a high incidence of bladder cancer drives the market growth in this region.
Europe (UK, Belgium, France, and Netherlands) is the second largest granulocyte- macrophage colony-stimulating factor market during the forecast period. The increasing occurrence of head and neck cancer drives the market in this region. According, to the National Center for Biotechnology Information (2014) report recombinant human granulocyte-macrophage-colony-stimulating factor plays important role in wound healing. Also, it is beneficial for chronic leg ulcers, deep partial-thickness burn wounds, and leprosy ulcers. According to Cancer Research UK in 2015, there were12, 061 new cases of head and neck cancer. Thus, the growing cases of cancer facilitate the market growth.
Asia-Pacific was projected to be the fastest growing region for the global granulocyte- macrophage colony-stimulating factor market in 2017. The market is expected to witness growth owing to the rising prevalence of fungal infection and smoking in this region. According to the World Health Organization in 2015, 47.6% of people smoked tobacco in Japan and China, respectively which can increase the cancer patient in this region. This is expected to provide favorable backgrounds for the market to grow in this region.
The Middle East and Africa accounts for the least share due to lack of availability of well-trained healthcare facility and low per capita income. However, the rising fungal infection and other wound-related problems are expected to influence the market in a positive way.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment